Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Perindopril erbumine
Drug ID BADD_D01740
Description Perindopril is a nonsulfhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly metabolized in the liver to perindoprilat, its active metabolite, following oral administration. Perindoprilat is a potent, competitive inhibitor of ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Perindopril may be used to treat mild to moderate essential hypertension, mild to moderate congestive heart failure, and to reduce the cardiovascular risk of individuals with hypertension or post-myocardial infarction and stable coronary disease.
Indications and Usage For the treatment of mild to moderate essential hypertension, mild to moderate congestive heart failure, and to reduce the cardiovascular risk of individuals with hypertension or post-myocardial infarction and stable coronary disease.
Marketing Status Prescription; Discontinued
ATC Code C09AA04
DrugBank ID DB00790
KEGG ID D00624
MeSH ID D020913
PubChem ID 441313
TTD Drug ID D03KYG
NDC Product Code 0054-0110; 65862-288; 66039-804; 65862-286; 0054-0112; 50370-0005; 65862-287; 15308-1000; 53104-7586; 0054-0111
Synonyms Perindopril | Pirindopril | S-9490 | S 9490 | S9490 | S 9490-3 | S 9490 3 | S 94903 | Perindopril Erbumine | Erbumine, Perindopril | Perstarium
Chemical Information
Molecular Formula C23H43N3O5
CAS Registry Number 107133-36-8
SMILES CCCC(C(=O)OCC)NC(C)C(=O)N1C2CCCCC2CC1C(=O)O.CC(C)(C)N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Blood pressure decreasedAngiotensin-converting enzymeP12821T82577Not Available
CoughB2 bradykinin receptorP30411T23714Not Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Thrombocytopenia01.08.01.002--Not Available
Tinnitus17.04.07.004; 04.04.01.002--
Tremor17.01.06.002--
Upper respiratory tract infection22.07.03.011; 11.01.13.009--
Urinary incontinence20.02.02.010; 17.05.01.008--
Urinary retention20.02.02.011--
Urinary tract infection20.08.02.001; 11.01.14.004--
Urticaria23.04.02.001; 10.01.06.001--
Vaginal infection21.14.02.002; 11.01.10.002--
Vaginal inflammation21.14.02.001--
Vascular purpura23.06.01.008; 01.01.04.007; 24.07.06.011--Not Available
Vasculitis24.05.02.001; 10.02.02.006--
Ventricular extrasystoles02.03.04.007--Not Available
Vertigo17.02.12.002; 04.04.01.003--
Viral infection11.05.04.001--Not Available
Visual impairment06.02.06.008--Not Available
Vomiting07.01.07.003--
Seasonal allergy22.04.04.008; 10.01.04.001; 06.04.01.013--Not Available
Peripheral swelling08.01.03.053; 02.05.04.015--Not Available
Red blood cell sedimentation rate increased13.01.03.001--Not Available
Protein urine present13.13.02.006--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Haemorrhage24.07.01.002--Not Available
Cognitive disorder19.21.02.001; 17.03.03.003--
Male sexual dysfunction21.03.02.012; 19.08.05.003--Not Available
Serositis08.01.05.006--Not Available
Vasodilation procedure25.03.01.001--Not Available
Urine output increased13.13.03.002--Not Available
Antinuclear antibody positive13.06.01.003--Not Available
Hot flush21.02.02.001; 24.03.01.005; 08.01.03.027--
The 6th Page    First    Pre   6 7    Next   Last    Total 7 Pages